



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: McDONALD et al.

Serial No. 09/360,242

Filed: July 22, 1999

For: *METHODS AND COMPOSITIONS FOR  
TREATING SECONDARY TISSUE DAMAGE  
AND OTHER INFLAMMATORY  
CONDITIONS AND DISORDERS*

Art Unit: 1646

Examiner: Landsman, R.

I hereby certify that this paper is being deposited  
with the United States Postal Service as first  
class mail in an envelope addressed to:  
Assistant Commissioner for Patents, Washington,  
D.C. 20231, on this date.

12/13/99  
Date

*Kathy Holloway*  
Kathy Holloway

RECEIVED

DEC 22 1999

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Responsive to the Office Action, mailed November 12, 1999, transmitted herewith  
are an Election, an Amendment and Response to the Notice to Comply with Requirements  
for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence  
Disclosures, paper and disk copies of the Substitute Sequence Listing, a Verified  
Statement that the paper and computer readable copies of the Substitute Sequence  
Listing are the same, and a copy of the Notice to Comply, and a DECLARATION regarding  
subject matter incorporated by reference that is added by way of amendment.

- ☒ The Commissioner is hereby authorized to charge any fee, including any  
submitted herewith if an attached check(s) is in the wrong amount or  
otherwise improper or missing, that may be due in connection with this and  
the attached papers, or with this application during its entire pendency to or  
to credit any overpayment to Deposit Account No. 08-1641. A duplicate of  
this sheet is enclosed.

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE

By: *Stephanie L. Seidman*  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 25020-601B  
Address all correspondence to:  
HELLER, EHRMAN, WHITE & McAULIFFE  
4250 Executive Square  
La Jolla, California 92037  
Telephone: 858 450-8400  
Facsimile: 619 587-5360  
email:sseidman@HEWM.com



Application No.: 09/1360

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**